The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant women and the effectiveness of these medications in reducing mother-to-child transmission. Therefore, although HCV screening during pregnancy is now recommended in many countries, there is no approved treatment for HCV during pregnancy. An observational study is here proposed to assess outcomes of mother-infant pairs exposed to DAAs during pregnancy within a global clinical case registry. Data regarding the exposures and outcomes of mother-infant pairs exposed to DAAs during pregnancy will be solicited and collected from clinical providers, healthcare facilities, HCV treatment programs, and other clinical practices worldwide. Data will be shared and maintained within a secure database, and cumulative data will be analyzed at pre-determined six-month intervals. The primary outcome will be the number and proportion of mother-infant pairs with adverse pregnancy or birth outcomes. The results of this study will inform HCV treatment decisions by clinical providers and programs worldwide.

In 2016, approximately 6% of all women who were tested for HCV during pregnancy in the United States were HCV antibody-positive. That year, there were 14,417 live births delivered by HCV-positive women, which comprised 0.38% of all live births in the US. Globally, the HCV prevalence among pregnant women varies widely (0.06%-7%) depending on regional and local epidemiology and risk factors. Approximately 5.8% of infants born to HCV-infected mothers will acquire HCV infection with higher rates of transmission among women with HIV co-infection. The primary route for the vertical transmission of HCV is believed to be the perinatal exposure of the infant to maternal blood, though in utero transmission also occurs.

Hepatitis C virus (HCV) testing for pregnant women is now recommended in many countries and universal HCV screening for pregnant women was adopted in the United States in 2020. No clinical interventions have been proven to reduce perinatal HCV transmission, but current and clinical practice guidelines include recommendations for the avoidance of potentially invasive procedures during delivery (ie, chorionic villus sampling, fetal scalp monitoring, episiotomy). The effect of virologic suppression or cure of HCV infection during pregnancy on the risk of mother-to-child HCV transmission has not been directly studied. Previous HCV treatment regimens were contra-indicated in pregnancy due to the inclusion of ribavirin and other teratogenic drugs. More recently, interferon- and ribavirin-free direct-acting antiviral (DAA) medications have raised the potential for HCV treatment during pregnancy to prevent perinatal transmission of HCV and allow for treatment of women during pregnancy. Over half of women reported a preference for HCV treatment during pregnancy if it reduced the probability of vertical transmission to the infant. In addition to potentially reducing vertical transmission to the infant during the current pregnancy, treatment during pregnancy can increase the number of women treated for HCV, and decrease the likelihood of being infected during subsequent pregnancies. Many vulnerable women are at high-risk for loss-to-follow-up following delivery and many women living with HCV may only be eligible for health insurance during pregnancy and immediately postpartum.

Several DAA regimens have demonstrated excellent safety and efficacy profiles in non-pregnant individuals across multiple or all HCV genotypes, achieving cure in \>95% of people in as few as 8 weeks of once-daily oral treatment. However, there are limited data regarding the safety and efficacy of DAAs in pregnancy. A phase I pharmacokinetic study of sofosbuvir/ledipasvir (SOF/LDV) in 9 pregnant women demonstrated similar drug levels to non-pregnant individuals with excellent safety and efficacy profile, and a similar study of sofosbuvir/velpatasvir (SOF/VEL) is currently enrolling participants. A prospective study of 15 women treated with SOF/LDV in India reported no adverse events. No other trials have been conducted or registered for pregnant individuals to date. The frequency and outcomes for women who become pregnant while on DAA treatment have been rarely reported. Currently, there is only one published study reporting outcomes of mother-infant pairs of women who became pregnant while on DAA treatment; among 100 women, 9 of whom completed 12 weeks of treatment with various regimens, no major adverse events were reported.

Given the paucity of data regarding the safety and efficacy of DAA treatment in pregnancy, the American College of Obstetrics and Gynecology and Society for Maternal-Fetal Medicine recommend that DAAs "only be initiated in the setting of a clinical trial during pregnancy and that people who become pregnant while taking a direct-acting antiviral should be counseled in a shared decision-making framework about the risks and benefits of continuation." The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases (IDSA/AASLD) advise that "treatment can be considered during pregnancy on an individual basis after a patient-physician discussion about the potential risks and benefits". Treatment for HCV in pregnancy therefore remains an off-label use of DAA medications and clinical practices remain highly variable by providers and programs. The frequency, geographic distribution, safety profile or effectiveness of HCV treatment during pregnancy for mother-infant pairs have not been evaluated or reported.

The primary objective of this observational study is to assess the safety of DAA treatment in mother-infant pairs with exposure to DAA medications during pregnancy within a clinical case registry. The secondary objectives of this study are to describe the frequency and distribution of known cases of DAA exposure during pregnancy and to assess the effectiveness of DAA treatment in pregnancy in achieving HCV cure for mothers and reducing the transmission of HCV from mother to infant.

This is an observational study of the outcomes of mother-infant pairs exposed to DAA treatment during pregnancy in routine clinical practice using de-identified data from a convenience sample of health facilities, public health, government, and private entities globally. Data regarding the demographics, baseline clinical status, timing and type of DAA exposure, and pregnancy/birth outcomes of mother-infant pairs exposed to DAAs during pregnancy will be solicited from clinical providers, health facilities, HCV treatment programs, and other clinical practices or programs prescribing DAA treatment. Data will be coded, standardized, and pooled in a common database for analysis.

Eligibility Criteria:
Inclusion Criteria:

-Documented pregnancy with: Estimated date of conception by documentation of either 1) date of last menstrual period or 2) ultrasound evaluation Actual date of delivery

* Documented chronic HCV infection prior to or during pregnancy (positive test for HCV RNA or HCV core antigen)
* Documented DAA exposure occurring within 30 days of the estimated date of conception and before the pregnancy outcome (ie, fetal demise, spontaneous abortion, live delivery, etc). Eligible DAA drugs are listed in Appendix 1.

Exclusion Criteria:

- DAA exposures that include ribavirin or interferon will be excluded given their established harm during pregnancy.